Publikationen

Aktuelle Publikationen

• Shumilov E*, Boyadzhiev H*, Mazzeo P, Akhoundova D, Daskalakis M, Novak U, Lenz G, Bacher U**, Pabst Th**. CAR-T cell therapy shows similar efficacy and toxicity in patients with DLBCL regardless of CNS involvement. HemaSphere. 2023; 7(12):p e984. doi: 10.1097/HS9.0000000000000984.
• Treiber H, Ganster C, Schanz J, Shimono J, Zechel S, Pohanyar N, Riedel C, Stadelmann C, Haase D, Trümper L, Chapuy B, Wulf GG. Clonal hematopoiesis with TET2 mutations spawning synchronous primary central nervous system lymphoma and myelodysplastic syndrome. Ann Hematol. 2023. doi: 10.1007/s00277-023-05430-z.
• Nilius-Eliliwi V^#, Treiber H^#, Seidel S, Vangala DB, Schroers R. High-dose chemotherapy and autologous stem cell transplantation in primary lymphomatoid granulomatosis of the central nervous system.J Cancer Res Clin Oncol. 2023;149(9):5729-5732. doi: 10.1007/s00432-022-04531-y.
• Treiber H, Nilius-Eliliwi V, Seifert N, Vangala D, Wang M, Seidel S, Mika T, Marschner D, Zeremski V, Wurm-Kuczera R, Caillé L, Chapuy CI, Trümper L, Fischer T, Altenbuchinger M, Wulf GG, Illerhaus G, Dietrich S, Schroers R, Chapuy B. Treatment strategies and prognostic factors in secondary central nervous system lymphoma: A multicenter study of 124 patients. HemaSphere. 2023;7(8):e926. doi: 10.1097/HS9.0000000000000926.
• Mallo M, Tuechler H, Arenillas L, Raynaud S, Cluzeau T, Shih LY, Tung-Liang C, Ganster C, Shirneshan K, Haase D, Mascaró M, Palomo L, Cervera J, Such E, Trim N, Jeffries S, Ridgway E, Marconi G, Martinelli G, Solé F. Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype. EJHaem. 2023;4(2):446-449. doi: 10.1002/jha2.651.
• Eder LN, Martinovic D, Mazzeo P, Ganster C, Hasenkamp J, Thomson J, Trummer A, Haase D, Wulf G. Fatal progression of mutated TP53-associated clonal hematopoiesis following anti-CD19 CAR-T cell therapy.Curr Oncol. 2023;30(1):1146-1150. doi: 10.3390/curroncol30010087.
• Braulke F, Schweighöfer A, Schanz J, Shirneshan K, Ganster C, Pollock-Kopp B, Leha A, Haase D. Cytogenetic peripheral blood monitoring in azacitidine treated patients with high-risk MDS/sAML: A monocentric real-world experience.Leuk Res. 2023;124:106996. doi: 10.1016/j.leukres.2022.

Publikationen 2022

• Platzbecker U, Götze KS, Kiewe P, Germing U, Mayer K, Radsak M, Wolff T, Chromik J, Sockel K, Oelschlägel U, Haase D, Illmer T, Al-Ali HK, Silling G, Reynolds JG, Zhang X, Attie KM, Shetty JK, Giagounidis A. Long-term efficacy and safety of luspatercept for anemia treatment in patients with lower-risk myelodysplastic syndromes: The phase II PACE-MDS study.J Clin Oncol. 2022;40(33):3800-3807. doi: 10.1200/JCO.21.02476. 
• Shumilov E, Hasenkamp J, Maulhardt M, Mazzeo P, Schmidt N, Boyadzhiev H, Jung W, Ganster C, Haase D, Koch R, Wulf G. Outcomes of second allogeneic stem cell transplantation and anti-relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis.Hematol Oncol. 2022;40(4):763-776. doi: 10.1002/hon.2995.
• Treiber H, von der Brelie C, Malinova V, Mielke D, Rohde V, Chapuy CI. Regorafenib for recurrent high-grade glioma: a unicentric retrospective analysis of feasibility, efficacy, and toxicity.Neurosurg Rev. 2022;45(5):3201-3208. doi: 10.1007/s10143-022-01826-z.
• Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Ossa JEA, Nannya Y, Devlin SM, Creignou M, Pinel P, Monnier L, Gundem G, Medina-Martinez JS, Domenico D, Jädersten M, Germing U, Sanz G, Loosdrecht AA van de, Kosmider O, Follo MY, Thol F, Zamora L, Pinheiro RF, Pellagatti A, Elias HK, Haase D, Ganster C, Ades L, Tobiasson M, Palomo L, Porta MGD, Takaori-Kondo A, Ishikawa T, Chiba S, Kasahara S, Miyazaki Y, Viale A, Huberman K, Fenaux P, Belickova M, Savona MR, Klimek VM, Santos FPS, Boultwood J, Kotsianidis I, Santini V, Solé F, Platzbecker U, Heuser M, Valent P, Ohyashiki K, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Gattermann N, Ebert BL, Bejar R, Malcovati L, Cazzola M, Ogawa S, Hellström-Lindberg E, Papaemmanuil E. Molecular international prognostic scoring system for myelodysplastic syndromes.NEJM Evid. 2022; 1(7):EVIDoa2200008. doi:10.1056/evidoa2200008.
• Akkari YMN, Baughn LB, Dubuc AM, Smith AC, Mallo M, Dal Cin P, Diez Campelo M, Gallego MS, Granada Font I, Haase DT, Schlegelberger B, Slavutsky I, Mecucci C, Levine RL, Hasserjian RP, Solé F, Levy B, Xu X. Guiding the global evolution of cytogenetic testing for hematologic malignancies.Blood. 2022;139(15):2273-2284. doi: 10.1182/blood.2021014309.
• Shumilov E, Mazzeo P, Zinkernagel MS, Legros M, Porret N, Romagna L, Haase D, Lenz G, Novak U, Banz Y, Pabst T, Bacher U. Comprehensive laboratory diagnostic workup for patients with suspected intraocular lymphoma including flow cytometry, molecular genetics and cytopathology.Curr Oncol. 2022;29(2):766-776. doi: 10.3390/curroncol29020065

Publikationen 2021

• Menck K, Heinrichs S, Wlochowitz D, Sitte M, Noeding H, Janshoff A, Treiber H, Ruhwedel T, Schatlo B, von der Brelie C, Wiemann S, Pukrop T, Beißbarth T, Binder C, Bleckmann A. WNT11/ROR2 signaling is associated with tumor invasion and poor survival in breast cancer.J Exp Clin Cancer Res. 2021;40(1):395. doi: 10.1186/s13046-021-02187-z.
• Müller D, Mazzeo P, Koch R, Bösherz MS, Welter S, Hammerstein-Equord A von, Hinterthaner M, Cordes L, Belharazem D, Marx A, Ströbel P, Küffer S. Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas.BMC Med. 2021;19(1):300. doi: 10.1186/s12916-021-02158-3.
• Kröger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D, Stadler M, Kobbe G, Wulf G, Bug G, Schäfer-Eckart K, Scheid C, Nolte F, Krönke J, Stelljes M, Beelen D, Heinzelmann M, Haase D, Buchner H, Bleckert G, Giagounidis A, Platzbecker U. Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study). J Clin Oncol. 2021;39(30):3318-3327. doi: 10.1200/JCO.20.02724.
• Petzold G, Bremer SCB, Heuschert FC, Treiber H, Ellenrieder V, Kunsch S, Neesse A. Tunnelled peritoneal catheter for malignant ascites—An open-label, prospective, observational trial.Cancers (Basel). 2021;13(12):2926. doi: 10.3390/cancers13122926.
• Treiber H, König A, Neesse A, Richter A, Sahlmann CO, Strauss A. Liver enzyme elevation after 177Lu-PSMA radioligand therapy for metastasized castration-resistant prostate cancer.J Nucl Med. 2021;62(7):1016-1019. doi: 10.2967/jnumed.120.258533. 
• Hecht A, Meyer JA, Jann JC, Sockel K, Giagounidis A, Götze KS, Letsch A, Haase D, Schlenk RF, Haferlach T, Schafhausen P, Bug G, Lübbert M, Thol F, Büsche G, Schuler E, Nowak V, Obländer J, Fey S, Müller N, Metzgeroth G, Hofmann WK, Germing U, Nolte F, Reinwald M, Nowak D. Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q). Ann Hematol. 2021;100(6):1463-1471. doi: 10.1007/s00277-021-04492-1.
• Panagiota V, Meggendorfer M, Kubasch AS, Gabdoulline R, Krönke J, Mies A, Shahswar R, Kandziora C, Klement P, Schiller J, Göhring G, Haferlach C, Ganster C, Shirneshan K, Gutermuth A, Thiede C, Germing U, Schroeder T, Kobbe G, Klesse S, Koenecke C, Schlegelberger B, Kröger N, Haase D, Döhner K, Sperr WR, Valent P, Ganser A, Thol F, Haferlach T, Platzbecker U, Heuser M. Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. Am J Hematol. 2021. 96(6):E207-E210. doi: 10.1002/ajh.26162.
• Hoffmüller P, Brüggemann M, Eggermann T, Ghoreschi K, Haase D, Hofmann J, Hunfeld KP, Koch K, Meisel C, Michl P, Müller J, Müller C, Rabenau HF, Reinhardt D, Riemenschneider MJ, Sachs UJ, Sack U, Stenzinger A, Streichert T, Neuhoff N von, Weichert W, Weinstock C, Zimmermann S, Spitzenberger F, Devices AA hoc CI vitro DM. Advisory opinion of the AWMF Ad hoc Commission In-vitro Diagnostic Medical Devices regarding in-vitro diagnostic medical devices manufactured and used only within health institutions established in the Union according to Regulation (EU) 2017/746 (IVDR). Gms Ger Medical Sci. 2021;19:Doc08. doi: 10.3205/000295.
• Hakroush S, Lehnig LY, Wallbach M, Schanz J, Koziolek MJ. Renal involvement of intravascular large B-cell lymphoma: a challenging diagnosis. J Nephrol. 2022;35(4):1295-1297. doi: 10.1007/s40620-021-01109-8.

Publikationen 2020

• Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, Haase D, Creignou M, Germing U, Zhang Y, Gundem G, Sarian A, Loosdrecht AA van de, Jädersten M, Tobiasson M, Kosmider O, Follo MY, Thol F, Pinheiro RF, Santini V, Kotsianidis I, Boultwood J, Santos FPS, Schanz J, Kasahara S, Ishikawa T, Tsurumi H, Takaori-Kondo A, Kiguchi T, Polprasert C, Bennett JM, Klimek VM, Savona MR, Belickova M, Ganster C, Palomo L, Sanz G, Ades L, Porta MGD, Smith AG, Werner Y, Patel M, Viale A, Vanness K, Neuberg DS, Stevenson KE, Menghrajani K, Bolton KL, Fenaux P, Pellagatti A, Platzbecker U, Heuser M, Valent P, Chiba S, Miyazaki Y, Finelli C, Voso MT, Shih L-Y, Fontenay M, Jansen JH, Cervera J, Atsuta Y, Gattermann N, Ebert BL, Bejar R, Greenberg PL, Cazzola M, Hellström-Lindberg E, Ogawa S, Papaemmanuil E. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26(10):1549-1556. doi: 10.1038/s41591-020-1008-z.
• Sill H, Zebisch A, Haase D. Acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations — A distinct stem cell disorder. Clin Cancer Res. 2020;26(20):5304-5309. doi: 10.1158/1078-0432.CCR-20-2272.
• Crisà E, Kulasekararaj AG, Adema V, Such E, Schanz J, Haase D, Shirneshan K, Best S, Mian SA, Kizilors A, Cervera J, Lea N, Ferrero D, Germing U, Hildebrandt B, Martínez ABV, Santini V, Sanz GF, Solé F, Mufti GJ. Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. Leukemia. 2020;34(9):2441-2450. doi: 10.1038/s41375-020-0728-x.
• Shumilov E, Hosseini ASA, Petzold G, Treiber H, Lotz J, Ellenrieder V, Kunsch S, Neesse A. Comparison of chest ultrasound and standard X-ray imaging in COVID-19 patients.Ultrasound Int Open. 2020;6(2):E36-E40. doi: 10.1055/a-1217-1603. 
• Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, Haferlach T, Heuser M, Jansen JH, Komrokji RS, Maciejewski JP, Walter MJ, Fontenay M, Garcia-Manero G, Graubert TA, Karsan A, Meggendorfer M, Pellagatti A, Sallman DA, Savona MR, Sekeres MA, Steensma DP, Tauro S, Thol F, Vyas P, Van de Loosdrecht AA, Haase D, Tüchler H, Greenberg PL, Ogawa S, Hellstrom-Lindberg E, Cazzola M. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020;136(2):157-170. doi: 10.1182/blood.2020004850.
• Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero G, Komrokji RS, Sekeres MA, Della Porta MG, Cazzola M, DeZern AE, Roboz GJ, Steensma DP, Van de Loosdrecht AA, Schlenk RF, Grau J, Calvo X, Blum S, Pereira A, Valent P, Costa D, Giagounidis A, Xicoy B, Döhner H, Platzbecker U, Pedro C, Lübbert M, Oiartzabal I, Díez-Campelo M, Cedena MT, Machherndl-Spandl S, López-Pavía M, Baldus CD, Martinez-de-Sola M, Stauder R, Merchan B, List A, Ganster C, Schroeder T, Voso MT, Pfeilstöcker M, Sill H, Hildebrandt B, Esteve J, Nomdedeu B, Cobo F, Haas R, Sole F, Germing U, Greenberg PL, Haase D, Sanz G. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.Leukemia. 2021;35(3):835-849. doi: 10.1038/s41375-020-0917-7. 

Publikationen 2019

• Haase D. Klonale Hämatopoese - Teil 1. best practice onkologie. 2019. 14(5):166-79.
• Haase D. Klonale Hämatopoese - Teil 2. best practice onkologie. 2019. 14(9):360-72.
• Mika T, Baraniskin A, Ladigan S, Wulf G, Dierks S, Haase D, Schork K, Turewicz M, Eisenacher M, Schmiegel W, Schroers R, Klein‐Scory S. Digital droplet PCR‐based chimerism analysis for monitoring of hematopoietic engraftment after allogeneic stem cell transplantation. Int J Lab Hematol. 2019;41(5):615-621. doi: 10.1111/ijlh.13073.
• Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, Loosdrecht AA van de, Haase D, Haferlach T, Elena C, Pleyer L, Kern W, Pemovska T, Vladimer GI, Schanz J, Keller A, Lubbert M, Lion T, Sotlar K, Reiter A, Witte TD, Pfeilstocker M, Geissler K, Padron E, Deininger M, Orfao A, Horny H-P, Greenberg PL, Arber DA, Malcovati L, Bennett JM. Proposed diagnostic criteria for classical CMML, CMML variants and pre-CMML conditions. Haematologica. 2019;104(10):1935-1949. doi: 10.3324/haematol.2019.222059.
• Ganster C, Müller-Thomas C, Haferlach C, Strupp C, Ogata K, Germing U, Hildebrandt B, Mallo M, Lübbert M, Müller C, Solé F, Götze KS, Vandenberghe P, Göhring G, Steinmetz T, Kröger N, Platzbecker U, Söling U, Raynaud S, Shirneshan K, Schanz J, Haase D. Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes. Genes Chromosomes Cancer. 2019. 58(10):689-697. doi: 10.1002/gcc.22760.
• Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. 2019. 33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. 
• Blazquez R, Rietkötter E, Wenske B, Wlochowitz D, Sparrer D, Vollmer E, Müller G, Seegerer J, Sun X, Dettmer K, Barrantes-Freer A, Stange L, Utpatel K, Bleckmann A, Treiber H, Bohnenberger H, Lenz C, Schulz M, Reimelt C, Hackl C, Grade M, Büyüktas D, Siam L, Balkenhol M, Stadelmann C, Kube D, Krahn MP, Proescholdt MA, Riemenschneider MJ, Evert M, Oefner PJ, Klein CA, Hanisch UK, Binder C, Pukrop T. LEF1 supports metastatic brain colonization by regulating glutathione metabolism and increasing ROS resistance in breast cancer.Int J Cancer. 2020;146(11):3170-3183. doi: 10.1002/ijc.32742.

Publikationen 2018

• Schanz J, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. Genes Chromosomes Cancer. 2018. 57(11):547-556.
• Martin R, Acha P, Ganster C, Palomo L, Dierks S, Fuster-Tormo F, Mallo M, Ademà V, Gómez-Marzo P, De Haro N, Solanes N, Zamora L, Xicoy B, Shirneshan K, Flach J, Braulke F, Schanz J, Kominowski A, Stromburg M, Brockmann A, Trümper L, Solé F, Haase D. Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes. Am J Hematol. 2018. 93(6):E152-E154.
• Schanz J, Cevik N, Fonatsch C, Braulke F, Shirneshan K, Bacher U, Haase D. Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders. Blood Cancer J. 2018. 8(3):28.

Publikationen 2017

• Braulke F, Schulz X, Germing U, Schuler E, Platzbecker U, Nolte F, Hofmann WK, Giagounidis A, Götze K, Lübbert M, Schlenk RF, Schanz J, Bacher U, Ganser A, Büsche G, Letsch A, Schafhausen P, Bug G, Brümmendorf TH, Haas R, Trümper L, Shirneshan K, Haase D. Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial. Ann Hematol. 2017. 96(6):887-894.

Publikationen 2016

• Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood. 2016. 128(16):2096-2097.

Publikationen 2015

• Ganster C, Kämpfe D, Jung K, Braulke F, Shirneshan K, Machherndl-Spandl S, Suessner S, Bramlage CP, Legler TJ, Koziolek MJ, Haase D, Schanz J. New data shed light on Y-loss-related pathogenesis in myelodysplastic syndromes. Genes Chromosomes Cancer. 2015. 54(12):717-24.
• Braulke F, Müller-Thomas C, Götze K, Platzbecker U, Germing U, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Hildebrandt B, Aul C, Stauder R, Valent P, Fonatsch C, Bacher U, Trümper L, Haase D, Schanz J. Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group. Genes Chromosomes Cancer. 2015. 54(12):809-17.
• Ganster C, Shirneshan K, Salinas-Riester G, Braulke F, Schanz J, Platzbecker U, Haase D. Influence of total genomic alteration and chromosomal fragmentation on response to a combination of azacitidine and lenalidomide in a cohort of patients with very high risk MDS. Leuk Res. 2015. 39(10):1079-87.
• Bacher U, Schanz J, Braulke F, Haase D. Leuk Res. 2015. 39(10):1079-87. Rare cytogenetic abnormalities in myelodysplastic syndromes. Mediterr J Hematol Infect Dis. 2015. 7(1):e2015034.
• Schanz J, Haase D, Steuernagel P, Shirneshan K, Bäsecke J. Primary osteomyelofibrosis and an XX-male genotype. Eur J Haematol. 2015. 95(3):254-6.

Publikationen 2014

• Braulke F, Platzbecker U, Müller-Thomas C, Götze K, Germing U, Brümmendorf TH, Nolte F, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Mallo M, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Shirneshan K, Aul C, Stauder R, Sperr WR, Valent P, Fonatsch C, Trümper L, Haase D, Schanz J. Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. Haematologica. 2015. 100(2):205-13.

Publikationen 2013

• Giagounidis A, Haase D. Morphology, cytogenetics and classification of MDS. Best Pract Res Clin Haematol. 2013. cc26(4):337-53.
• Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Grau J, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D.  Monosomal karyotype in MDS: explaining the poor prognosis? Leukemia. 2013. 27(10):1988-95.
• Braulke F, Jung K, Schanz J, Götze K, Müller-Thomas C, Platzbecker U, Germing U, Brümmendorf TH, Bug G, Ottmann O, Giagounidis AA, Stadler M, Hofmann WK, Schafhausen P, Lübbert M, Schlenk RF, Blau IW, Ganster C, Pfeiffer S, Shirneshan K, Metz M, Detken S, Seraphin J, Jentsch-Ullrich K, Böhme A, Schmidt B, Trümper L, Haase D. Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study. Leuk Res. 2013. 37(8):900-6.
• Hartmann J, Braulke F, Sinzig U, Wulf G, Maas JH, Konietschke F, Haase D.Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes. Leuk Res. 2013. 37(3):327-32.

Publikationen 2012

• Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012. 120(12):2454-65.
• Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012. 30(8):820-9.

Publiaktionen 2011

• Platzbecker U, Santini V, Mufti GJ, Haferlach C, Maciejewski JP, Park S, Solé F, van de Loosdrecht AA, Haase D. Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop. Leuk Res. 2012. 36(3):264-70.
• Braulke F, Schanz J, Steffens R, Liehr T, Manvelyan M, Chudoba I, Haase D. Two different del(5q) clones in a patient with myelodysplastic syndrome. Leuk Lymphoma. 2011. 52(9):1811-4.
• Schanz J, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H, Valent P, Hildebrandt B, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Kantarjian H, Germing U, Haase D, Estey E. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol. 2011. 29(15):1963-70.